Search
Spotlight
The OncLive Insider app is live!
CME Opportunities
The OncLive Insider app is live!
CME Opportunities
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Partners
Publications
Resources
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
The OncLive Insider app is live!
CME Opportunities
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Adjuvant Therapy for Early-Stage HER2-Positive Breast Cancer
EP. 1: Adjuvant Therapy for Early-Stage HER2+ Breast Cancer
February 2nd 2018
EP. 2: The APHINITY Trial
February 2nd 2018
EP. 3: The ExteNET Trial
February 2nd 2018
EP. 4: Factors Influencing Adjuvant Therapy Use for HER2+ Breast Cancer
February 2nd 2018
EP. 5: Which Chemotherapy With Adjuvant Trastuzumab and Pertuzumab?
February 2nd 2018
EP. 6: Optimal Timing for Neratinib
February 2nd 2018
EP. 7: Diarrhea Prophylaxis With Neratinib
February 2nd 2018
EP. 8: Role for Neratinib Following Adjuvant Dual-Targeted HER2 Therapy
February 2nd 2018
EP. 9: Treating Patients with HER2+ Breast Cancer: Impact of Cost
February 2nd 2018
EP. 10: Breast Cancer: Factors to Consider for Adjuvant Therapy
February 2nd 2018
EP. 11: Adjuvant Therapy Data for HER2-Positive Breast Cancer
February 2nd 2018
EP. 12: Chemotherapy With Adjuvant Therapy in Breast Cancer
February 2nd 2018
EP. 13: Use of Neratinib in HER2-Positive Breast Cancer
February 2nd 2018
EP. 14: Breast Cancer: Extended Adjuvant Therapy and Cost Factors
February 2nd 2018
EP. 15: Treatment Landscape for HER2-Positive Breast Cancer
February 2nd 2018
EP. 16: Priority Reviews in Ovarian Cancer, Prostate Cancer, NSCLC, and More
February 2nd 2018
x